<p>Dyne Therapeutics, Inc.（纳斯达克代码：DYN - 免费报告）- HC Wainwright 的投资分析师在 5 月 12 日星期二向投资者发布的报告中上调了 Dyne Therapeutics 2026 年第二季度每股收益（EPS）预期。HC Wainwright 分析师 A. Ghosh 现在预计该公司本季度每股收益为（$0.68），高于之前的预期（$0.76）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 $50.00。市场普遍预计 Dyne Therapeutics 当前全年的每股收益为（$2.97）。HC Wainwright 还发布了 Dyne Therapeutics 2026 年第三季度每股收益预期为（$0.68），第四季度每股收益预期为（$0.68），2026 财年每股收益预期为（$2.78），2027 财年每股收益预期为（$2.27），2028 财年每股收益预期为（$0.85），2029 财年每股收益预期为 $0.52，2030 财年每股收益预期为 $2.26。</p>
<p>获取 <strong>Dyne Therapeutics</strong> 警报：</p>
<p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）上一次发布季度财报是在 5 月 11 日星期一。该公司报告本季度每股收益为（$0.73），超出市场普遍预期的（$0.77）$0.04。在去年同期，该公司每股收益为（$1.05）。</p>
<p>其他一些研究公司也对 DYN 发布了报告。摩根士丹利在 3 月 2 日的研究报告中将 Dyne Therapeutics 的目标价从 $50.00 下调至 $47.00，并对该股票给予 “增持” 评级。Chardan Capital 在 3 月 9 日的研究报告中重申了 “买入” 评级，并对 Dyne Therapeutics 的股票设定了 $38.00 的目标价。华尔街 Zen 在 5 月 2 日的研究报告中将 Dyne Therapeutics 的股票评级从 “卖出” 下调至 “强烈卖出”。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Dyne Therapeutics 的 “卖出（d-）” 评级。最后，杰富瑞金融集团在 3 月 9 日的研究报告中重申了对 Dyne Therapeutics 的 “买入” 评级。三位投资分析师对该股票给予了强烈买入评级，十一位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Dyne Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 $35.21。</p>
<p><strong>获取我们关于 Dyne Therapeutics 的最新研究报告</strong></p>
<h2>Dyne Therapeutics 股票上涨 0.4%</h2>
<p>Dyne Therapeutics 股票在星期四开盘价为 $18.44。该公司的市值为 $30.5 亿，市盈率为 -5.73，贝塔值为 1.08。该公司的 50 日简单移动平均线为 $18.22，200 日简单移动平均线为 $18.63。该公司的流动比率为 19.92，速动比率为 22.25，债务与股本比率为 0.17。Dyne Therapeutics 的一年低点为 $8.06，一年高点为 $25.00。</p>
<h2>机构投资者对 Dyne Therapeutics 的看法</h2>
<p>几家对冲基金最近对该股票的持仓进行了调整。Dimensional Fund Advisors LP 在第一季度将其在 Dyne Therapeutics 的股份增加了 870.3%。Dimensional Fund Advisors LP 现在拥有 951,589 股该公司的股票，价值 $17,244,000，此前在此期间又购买了 853,515 股。瑞士国家银行在第一季度将其在 Dyne Therapeutics 的股份增加了 2.5%。瑞士国家银行现在拥有 228,100 股该公司的股票，价值 $4,135,000，此前在此期间又购买了 5,600 股。Assetmark Inc. 在第一季度购买了 Dyne Therapeutics 的新股份，价值约 $563,000。纽约梅隆银行在第一季度将其在 Dyne Therapeutics 的股份增加了 13.6%。纽约梅隆银行现在拥有 401,616 股该公司的股票，价值 $7,281,000，此前在此期间又购买了 48,119 股。最后，Fifth Third Bancorp 在第一季度购买了 Dyne Therapeutics 的新股份，价值约 $983,000。机构投资者持有该公司 96.68% 的股份。</p>
<h2>Dyne Therapeutics 的内部买卖</h2>
<p>在相关消息中，董事 Jason P. Rhodes 于 5 月 6 日星期三出售了 83,219 股该股票。股份以平均价格 $18.18 出售，总价值为 $1,512,921.42。出售完成后，该董事在公司中持有 7,962 股，价值约 $144,749.16。此交易代表其持股比例减少了 91.27%。该交易已在证券交易委员会的备案中披露，可以通过此超链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内共出售了 1,552,911 股公司股票，价值 $29,694,469。目前公司内部人士持有 14.14% 的股票。</p>
<h2>更多 Dyne Therapeutics 新闻</h2>
<p>以下是本周影响 Dyne Therapeutics 的主要新闻：</p>
<ul>
<li>积极情绪：HC Wainwright 和 Lifesci Capital 都上调了 Dyne Therapeutics 的近期收益预期，包括 2026 年第二季度、第三季度和第四季度，表明分析师对这家临床阶段生物技术公司的短期前景持更乐观的看法。Dyne Therapeutics 分析师更新</li>
<li>积极情绪：HC Wainwright 维持对 DYN 的 “买入” 评级和 “$50 目标价”，尽管公司持续亏损，但仍强化了看涨观点。HC Wainwright 报告</li>
<li>中性情绪：Dyne Therapeutics 表示管理层将参加即将举行的投资者会议，这是一次常规的投资者关系更新，可能有助于保持股票的关注，但本身并不会改变基本面。Dyne Therapeutics 投资者会议</li>
<li>消极情绪：一些长期预期被下调，包括 2027 财年、2028 财年、2029 财年和 2030 财年每股收益预测，这可能会抑制对 Dyne 长期收益路径的热情。Dyne Therapeutics 长期预期下调</li>
</ul>
<h2>关于 Dyne Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Dyne Therapeutics 是一家临床阶段的生物技术公司，专注于为严重罕见疾病开发局部基因调控疗法。该公司的专有 FORCE（促进的正交受体介导的载荷评估）平台旨在实现寡核苷酸和基因治疗方式的靶向递送，主要针对骨骼和呼吸肌肉。Dyne 的主要项目集中在杜氏肌营养不良症（DMD）、肌强直性营养不良症 1 型（DM1）和面肩肱肌营养不良症（FSHD），目前正在进行安全性、耐受性和组织特异性的临床前和早期临床研究。</p>
<p>自 2019 年由 Flagship Pioneering 创立以来，Dyne 利用其模块化递送方法推进了多个产品候选者，该方法将工程化配体与治疗载荷结合，以改善肌肉细胞的摄取。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Dyne Therapeutics 更好的股票</li>
<li>Oklo 股票可能准备再次大幅上涨</li>
<li>D-Wave 的财报看起来疲弱，但投资者可能忽视了这一点</li>
<li>随着 AI 反馈循环加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Dyne Therapeutics 吗？</h2>
<p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Dyne Therapeutics 并不在名单上。</p>
<p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>HC Wainwright 将 Dyne Therapeutics (NASDAQ:DYN) 2026 年第二季度每股收益预期从（$0.76）上调至（$0.68），维持 “买入” 评级，目标价为 $50.00。市场对该公司全年收益的共识预期为每股（$2.97）。Dyne 的股票开盘价为 $18.44，市值为 $30.5 亿。机构投资者持有该股票的 96.68%，最近的内部交易中，董事 Jason P. Rhodes 出售了 83,219 股。总体而言，Dyne Therapeutics 的共识评级为 “适度买入”，平均目标价为 $35.21</p>

<p>Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Investment analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Dyne Therapeutics in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.76). HC Wainwright has a &#34;Buy&#34; rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for Dyne Therapeutics' Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.78) EPS, FY2027 earnings at ($2.27) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at $0.52 EPS and FY2030 earnings at $2.26 EPS.</p>
<div class="lb-trans"><p>Dyne Therapeutics, Inc.（纳斯达克代码：DYN - 免费报告）- HC Wainwright 的投资分析师在 5 月 12 日星期二向投资者发布的报告中上调了 Dyne Therapeutics 2026 年第二季度每股收益（EPS）预期。HC Wainwright 分析师 A. Ghosh 现在预计该公司本季度每股收益为（$0.68），高于之前的预期（$0.76）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 $50.00。市场普遍预计 Dyne Therapeutics 当前全年的每股收益为（$2.97）。HC Wainwright 还发布了 Dyne Therapeutics 2026 年第三季度每股收益预期为（$0.68），第四季度每股收益预期为（$0.68），2026 财年每股收益预期为（$2.78），2027 财年每股收益预期为（$2.27），2028 财年每股收益预期为（$0.85），2029 财年每股收益预期为 $0.52，2030 财年每股收益预期为 $2.26。</p>
</div><p>Get <strong>Dyne Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dyne Therapeutics</strong> 警报：</p>
</div><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the firm earned ($1.05) EPS.</p>
<div class="lb-trans"><p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）上一次发布季度财报是在 5 月 11 日星期一。该公司报告本季度每股收益为（$0.73），超出市场普遍预期的（$0.77）$0.04。在去年同期，该公司每股收益为（$1.05）。</p>
</div><p>A number of other research firms have also issued reports on DYN. Morgan Stanley lowered their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, March 2nd. Chardan Capital reiterated a &#34;buy&#34; rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen lowered shares of Dyne Therapeutics from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research note on Saturday, May 2nd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, Jefferies Financial Group reiterated a &#34;buy&#34; rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $35.21.</p>
<div class="lb-trans"><p>其他一些研究公司也对 DYN 发布了报告。摩根士丹利在 3 月 2 日的研究报告中将 Dyne Therapeutics 的目标价从 $50.00 下调至 $47.00，并对该股票给予 “增持” 评级。Chardan Capital 在 3 月 9 日的研究报告中重申了 “买入” 评级，并对 Dyne Therapeutics 的股票设定了 $38.00 的目标价。华尔街 Zen 在 5 月 2 日的研究报告中将 Dyne Therapeutics 的股票评级从 “卖出” 下调至 “强烈卖出”。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Dyne Therapeutics 的 “卖出（d-）” 评级。最后，杰富瑞金融集团在 3 月 9 日的研究报告中重申了对 Dyne Therapeutics 的 “买入” 评级。三位投资分析师对该股票给予了强烈买入评级，十一位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Dyne Therapeutics 目前的共识评级为 “适度买入”，平均目标价为 $35.21。</p>
</div><p><strong>Get Our Latest Research Report on Dyne Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Dyne Therapeutics 的最新研究报告</strong></p>
</div><h2>Dyne Therapeutics Stock Up 0.4%</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 股票上涨 0.4%</h2>
</div><p>Dyne Therapeutics stock opened at $18.44 on Thursday. The company has a market capitalization of $3.05 billion, a P/E ratio of -5.73 and a beta of 1.08. The firm's fifty day simple moving average is $18.22 and its 200-day simple moving average is $18.63. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00.</p>
<div class="lb-trans"><p>Dyne Therapeutics 股票在星期四开盘价为 $18.44。该公司的市值为 $30.5 亿，市盈率为 -5.73，贝塔值为 1.08。该公司的 50 日简单移动平均线为 $18.22，200 日简单移动平均线为 $18.63。该公司的流动比率为 19.92，速动比率为 22.25，债务与股本比率为 0.17。Dyne Therapeutics 的一年低点为 $8.06，一年高点为 $25.00。</p>
</div><h2>Institutional Investors Weigh In On Dyne Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Dyne Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Dyne Therapeutics by 870.3% in the first quarter. Dimensional Fund Advisors LP now owns 951,589 shares of the company's stock valued at $17,244,000 after buying an additional 853,515 shares during the period. Swiss National Bank lifted its stake in shares of Dyne Therapeutics by 2.5% in the first quarter. Swiss National Bank now owns 228,100 shares of the company's stock valued at $4,135,000 after buying an additional 5,600 shares during the period. Assetmark Inc. bought a new stake in shares of Dyne Therapeutics in the first quarter valued at about $563,000. Bank of New York Mellon Corp lifted its stake in shares of Dyne Therapeutics by 13.6% in the first quarter. Bank of New York Mellon Corp now owns 401,616 shares of the company's stock valued at $7,281,000 after buying an additional 48,119 shares during the period. Finally, Fifth Third Bancorp bought a new stake in shares of Dyne Therapeutics in the first quarter valued at about $983,000. Institutional investors own 96.68% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近对该股票的持仓进行了调整。Dimensional Fund Advisors LP 在第一季度将其在 Dyne Therapeutics 的股份增加了 870.3%。Dimensional Fund Advisors LP 现在拥有 951,589 股该公司的股票，价值 $17,244,000，此前在此期间又购买了 853,515 股。瑞士国家银行在第一季度将其在 Dyne Therapeutics 的股份增加了 2.5%。瑞士国家银行现在拥有 228,100 股该公司的股票，价值 $4,135,000，此前在此期间又购买了 5,600 股。Assetmark Inc. 在第一季度购买了 Dyne Therapeutics 的新股份，价值约 $563,000。纽约梅隆银行在第一季度将其在 Dyne Therapeutics 的股份增加了 13.6%。纽约梅隆银行现在拥有 401,616 股该公司的股票，价值 $7,281,000，此前在此期间又购买了 48,119 股。最后，Fifth Third Bancorp 在第一季度购买了 Dyne Therapeutics 的新股份，价值约 $983,000。机构投资者持有该公司 96.68% 的股份。</p>
</div><h2>Insider Buying and Selling at Dyne Therapeutics</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 的内部买卖</h2>
</div><p>In related news, Director Jason P. Rhodes sold 83,219 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total value of $1,512,921.42. Following the completion of the sale, the director owned 7,962 shares in the company, valued at approximately $144,749.16. This trade represents a 91.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,552,911 shares of company stock valued at $29,694,469 in the last three months. 14.14% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Jason P. Rhodes 于 5 月 6 日星期三出售了 83,219 股该股票。股份以平均价格 $18.18 出售，总价值为 $1,512,921.42。出售完成后，该董事在公司中持有 7,962 股，价值约 $144,749.16。此交易代表其持股比例减少了 91.27%。该交易已在证券交易委员会的备案中披露，可以通过此超链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内共出售了 1,552,911 股公司股票，价值 $29,694,469。目前公司内部人士持有 14.14% 的股票。</p>
</div><h2>More Dyne Therapeutics News</h2>
<div class="lb-trans"><h2>更多 Dyne Therapeutics 新闻</h2>
</div><p>Here are the key news stories impacting Dyne Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Dyne Therapeutics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright and Lifesci Capital both raised near-term earnings estimates for Dyne Therapeutics, including Q2, Q3, and Q4 2026, suggesting analysts see a better short-term outlook for the clinical-stage biotech. Dyne Therapeutics analyst updates</li>
<li>Positive Sentiment: HC Wainwright kept its <strong>Buy</strong> rating and <strong>$50 price target</strong> on DYN, reinforcing a bullish view despite the company’s ongoing losses. HC Wainwright note</li>
<li>Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, a routine investor-relations update that may help keep the stock in focus but does not by itself change fundamentals. Dyne Therapeutics investor conferences</li>
<li>Negative Sentiment: Some longer-dated estimates were cut, including FY2027, FY2028, FY2029, and FY2030 EPS forecasts, which may temper enthusiasm about Dyne’s long-term earnings path. Dyne Therapeutics longer-term estimate cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 和 Lifesci Capital 都上调了 Dyne Therapeutics 的近期收益预期，包括 2026 年第二季度、第三季度和第四季度，表明分析师对这家临床阶段生物技术公司的短期前景持更乐观的看法。Dyne Therapeutics 分析师更新</li>
<li>积极情绪：HC Wainwright 维持对 DYN 的 “买入” 评级和 “$50 目标价”，尽管公司持续亏损，但仍强化了看涨观点。HC Wainwright 报告</li>
<li>中性情绪：Dyne Therapeutics 表示管理层将参加即将举行的投资者会议，这是一次常规的投资者关系更新，可能有助于保持股票的关注，但本身并不会改变基本面。Dyne Therapeutics 投资者会议</li>
<li>消极情绪：一些长期预期被下调，包括 2027 财年、2028 财年、2029 财年和 2030 财年每股收益预测，这可能会抑制对 Dyne 长期收益路径的热情。Dyne Therapeutics 长期预期下调</li>
</ul>
</div><h2>About Dyne Therapeutics</h2>
<div class="lb-trans"><h2>关于 Dyne Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.</p>
<div class="lb-trans"><p>Dyne Therapeutics 是一家临床阶段的生物技术公司，专注于为严重罕见疾病开发局部基因调控疗法。该公司的专有 FORCE（促进的正交受体介导的载荷评估）平台旨在实现寡核苷酸和基因治疗方式的靶向递送，主要针对骨骼和呼吸肌肉。Dyne 的主要项目集中在杜氏肌营养不良症（DMD）、肌强直性营养不良症 1 型（DM1）和面肩肱肌营养不良症（FSHD），目前正在进行安全性、耐受性和组织特异性的临床前和早期临床研究。</p>
</div><p>Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.</p>
<div class="lb-trans"><p>自 2019 年由 Flagship Pioneering 创立以来，Dyne 利用其模块化递送方法推进了多个产品候选者，该方法将工程化配体与治疗载荷结合，以改善肌肉细胞的摄取。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Dyne Therapeutics</li>
<li>Oklo Stock Could Be Ready for Another Massive Run</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Dyne Therapeutics 更好的股票</li>
<li>Oklo 股票可能准备再次大幅上涨</li>
<li>D-Wave 的财报看起来疲弱，但投资者可能忽视了这一点</li>
<li>随着 AI 反馈循环加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DYN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Dyne Therapeutics 吗？</h2>
</div><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Dyne Therapeutics 并不在名单上。</p>
</div><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright Has Optimistic Outlook of DYN Q2 Earnings

Market Beat

Dyne Therapeutics

摩根士丹利

Jefferies Financial

纽约梅隆银行

五三银行

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

五三银行-存托优先股Series K

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

五三银行-Series A

HC Wainwright 对 Dyne Therapeutics 第二季度的收益持乐观态度